TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11284758
Drug: Topical Ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Ketorolac trometamol 0.5% ophthalmic solution
Study: 8190431
Drug: Strict control
Normalized name: Euphrasia stricta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict control (n=68): fasting blood glucose < 4.44 mmol/L and postprandial blood glucose < 6.66 mmol/L
Study: 8190431
Drug: Customary control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customary control (n=69): fasting blood glucose < 5.55 mmol/L and postprandial blood glucose < 7.77 mmol/L
Study: 30476251
Drug: Atorvastatin (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (starting dose 80 mg PO daily)
Study: 28345432
Drug: Sildenafil citrate,
Normalized name: Sildenafil Citrate, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil citrate, 50 mg
Study: 20442354
Drug: Finasteride 1
Normalized name: finasteride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 1 mg orally daily
Study: 9933794
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day of urapidil for 4 weeks
Study: 9843009
Drug: 0.05% retinoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% retinoic acid cream
Study: 25123060
Drug: DHA-O (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-O (2.4 g/day DHA and EPA in a 2.7:1 ratio)
Study: 25123060
Drug: Fish Oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish Oil (FO; 2.0 g/day DHA and EPA in a 0.7:1 ratio)
Study: 17324401
Drug: Capsule Endoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule Endoscopy (CE)
Study: 16760508
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (1 mg/d)
Study: 17377120
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg dexamethasone IV
Study: 26370724
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL saline
Study: 9588451
Drug: Insulin response
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin response to a 75‐g oral glucose load in nonrelatives
Study: 9588451
Drug: Insulin response
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin response to a 75‐g oral glucose load in relatives
Study: 9588451
Drug: Multivariate analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivariate analysis for insulin response in nonrelatives
Study: 9588451
Drug: Multivariate analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivariate analysis for insulin response in relatives
Study: 7979639
Drug: Propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 160 mg LA
Study: 2609241
Drug: PGE1 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE1 (60 micrograms i.v. infusion daily for 3 weeks)
Study: 2609241
Drug: Naftidrofuryl (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (600 mg daily for 3 weeks)
Study: 27469294
Drug: Short dental
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short dental implants (6-8 mm)
Study: 27469294
Drug: Long dental
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long dental implants (11 mm)
Study: 12777590
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (other antibiotics)
Study: 10711911
Drug: Risperidone (4-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (4-10 mg)
Study: 10711911
Drug: Haloperidol (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5-20 mg)
Study: 3919555
Drug: bepridil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: bepridil (400 mg once a day)
Study: 31169354
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel (Stratacel®; Stratpharma) applied twice a day for 7 days
Study: 31169354
Drug: Petrolatum-based ointment
Normalized name: PETROLATUM BASE
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petrolatum-based ointment applied twice a day for 7 days
Study: 29431785
Drug: Glucono‐delta‐lactone (GDL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucono‐delta‐lactone (GDL) 2000 mg day‐1
Study: 27352486
Drug: Body acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body acupuncture and conventional western medication (both groups)
Study: 22013100
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy targeting normoglycemia (80‐110 mg/dl)
Study: 22013100
Drug: Tolerating hyperglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolerating hyperglycemia up to 215 mg/dl
Study: 17728050
Drug: Sildenafil as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil as monotherapy
Study: 17728050
Drug: Sildenafil in
Normalized name: sildenafil Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil in combination with SSRI (paroxetine)
Study: 28027198
Drug: Topical anesthetics
Normalized name: topical anesthetics (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthetics
Study: 15914256
Drug: Standardized physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized physical therapy plus 4 music therapy sessions
Study: 15914256
Drug: Standardized physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized physical therapy alone
Study: 10768630
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone sodium succinate treatment
Study: 8829312
Drug: Melatonin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (40 mg/day orally in the evening, starting 7 days prior to cytokine injection)
Study: 8829312
Drug: Cytokine alone
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine alone (IL-2: 3 x 10(6) IU/day s.c. every day, 6 days/week for 4 weeks; TNF: 0.75 mg/day i.v. for 5 days)
Study: 1313875
Drug: 4.1 g
Normalized name: psyllium 4.1 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.1 g daily fibre supplementation
Study: 3881913
Drug: Long-term Verapamil
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term Verapamil therapy
Study: 31344685
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 5000 IU daily
Study: 29901760
Drug: Leucine (LEU;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucine (LEU; 10 g milk protein with 3 g total l-leucine)
Study: 29901760
Drug: Whey Protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey Protein Isolate (WPI; 25 g WPI with 3 g l-leucine)
Study: 19960492
Drug: Citalopram (CIT)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram (CIT) with dose escalation (20-60 mg/day)
Study: 12891211
Drug: 3.5 g
Normalized name: Calcium 760 MG/3.5 GM Oral Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 g of fish oil daily for 12 weeks
Study: 12891211
Drug: Placebo oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oil daily for 12 weeks
Study: 10684161
Drug: Ferrous fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous fumarate (60 mg elemental Fe) daily
Study: 10684161
Drug: Ferrous fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous fumarate (60 mg elemental Fe) intermittently (three times a week)
Study: 30217371
Drug: AZL-M 80
Normalized name: M
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZL-M 80 mg
Study: 30217371
Drug: AZL-M/CLD 40/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZL-M/CLD 40/25 mg
Study: 30217371
Drug: AZL-M/CLD 80/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZL-M/CLD 80/25 mg
Study: 27169436
Drug: Community exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community exercise program (year-long, at least twice per week, supervised by a case manager)
Study: 22659765
Drug: Topical gentamicin-collagen
Normalized name: gentamicin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gentamicin-collagen sponge plus standard of care
Study: 17584482
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) in the priming solution
Study: 15805350
Drug: Comprehensive regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive regional hospital-based parent education program about violent infant shaking, administered at the time of the child's birth.
Study: 9871429
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg orally once a day for 5 days, followed by 80 mg tamoxifen on the sixth day.
Study: 9871429
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg orally once a day for 5 days, followed by 120 mg toremifene on the sixth day.
Study: 7610930
Drug: Oral 1,25(OH)2D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 1,25(OH)2D (Rocaltrol) 0.5 microgram twice a day for 5 days
Study: 2694180
Drug: arbaprostil 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: arbaprostil 10 mcg
Study: 2694180
Drug: arbaprostil 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: arbaprostil 25 mcg
Study: 2694180
Drug: arbaprostil 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: arbaprostil 50 mcg
Study: 2694180
Drug: arbaprostil 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: arbaprostil 400 mcg
Study: 2694180
Drug: arbaprostil 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: arbaprostil 1200 mcg
Study: 2694180
Drug: arbaprostil 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: arbaprostil 1600 mcg
Study: 21893693
Drug: Melatonin (MEL)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (MEL) 5 mg daily at bedtime
Study: 14557857
Drug: Bolus-titrated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus-titrated therapy (flunitrazepam, clonidine, haloperidol adjusted as needed)
Study: 14557857
Drug: Infusion-titrated therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion-titrated therapy (continuous infusion of flunitrazepam, clonidine, haloperidol)
Study: 8268342
Drug: Halofantrine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine (500 mg daily for 3 days)
Study: 8268342
Drug: Halofantrine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine (500 mg daily for 6 days)
Study: 8268342
Drug: Chloroquine (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (total dose of 1,500 mg over 3 days)
Study: 17012871
Drug: Licensed vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed vaccine (DTaP-IPV//PRP-T)
Study: 10447904
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion in conjunction with epidural ropivacaine and isoflurane anaesthesia
Study: 28215665
Drug: 1 year
Normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year of trastuzumab (8 mg/kg IV once, then 6 mg/kg every 3 weeks)
Study: 28215665
Drug: 2 years
Normalized name: Childrens Panadol 5 - 12 Years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 years of trastuzumab (8 mg/kg IV once, then 6 mg/kg every 3 weeks)
Study: 26284747
Drug: Control (Glasses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Glasses Prescriptions Only)
Study: 16580575
Drug: Extended-release metoprolol
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release metoprolol succinate (25, 100, or 400 mg)
Study: 16580575
Drug: Extended-release felodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release felodipine (2.5, 10, or 20 mg)
Study: 16580575
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of extended-release metoprolol succinate and extended-release felodipine (various combinations)
Study: 16580575
Drug: Low-dose combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combination (ER metoprolol succinate 25 mg/ER felodipine 2.5 mg)
Study: 10669338
Drug: HIV human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HIV human hyperimmune immunoglobulin (HIVIG) 200 mg/kg
Study: 10669338
Drug: HIV human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HIV human hyperimmune immunoglobulin (HIVIG) 400 mg/kg
Study: 10669338
Drug: HIV human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HIV human hyperimmune immunoglobulin (HIVIG) 800 mg/kg
Study: 1593359
Drug: Furosemide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (1 mg/kg per dose) intravenously every 24 hours for five doses
Study: 1593359
Drug: Furosemide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (1 mg/kg per dose) with metolazone (0.2 mg/kg per dose) enterally with doses 3 and 4 of furosemide
Study: 1593359
Drug: Metolazone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metolazone (0.2 mg/kg per dose) enterally every 24 hours for five doses
Study: 22450530
Drug: 400 ml
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 ml of oral 12.5% carbohydrate solution
Study: 18690345
Drug: Estradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (2 mg) + trimegestone (0.5 mg)
Study: 18690345
Drug: Estradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (2 mg) + dydrogesterone (10 mg)
Study: 1111446
Drug: Prophylactic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic heparin or aspirin
Study: 28806217
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg intravenous ondansetron
Study: 22330131
Drug: HCl infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCl infusion (0.15 M for 30 minutes)
Study: 18827611
Drug: Oral plus
Normalized name: Acetaminophen/Dexbrompheniramine Maleate/Pseudoephedrine Hydrochloride 500 MG-3 MG-60 MG Oral Tablet, Extended Release [DRIXORAL PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral plus written information
Study: 11179942
Drug: Oral information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral information only
Study: 15927054
Drug: Functional Assessment
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Assessment of Cancer Therapy‐‐General
Study: 15927054
Drug: European Organization
Approvals — FDA: no, EMA: no, PMDA: no
Description: European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire
Study: 9538308
Drug: Metoprolol CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR (100 mg once daily)
Study: 27605629
Drug: ISIS 388626
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 388626 (200 mg)
Study: 27605629
Drug: ISIS 388626
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 388626 (100 mg)
Study: 21239075
Drug: High-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clopidogrel (150 mg/day for 1 month)
Study: 21239075
Drug: Standard-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose clopidogrel (75 mg/day for 1 month)
Study: 21239075
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (75 mg/day for 1 month)
Study: 26876716
Drug: CCR4 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CCR4 antagonist
Study: 18719447
Drug: Morphine patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine patient‐controlled analgesia
Study: 16115358
Drug: CLA-enriched dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLA-enriched dairy products (1.43 g c9,t11 CLA/d; 4.71 g tVA/d)
Study: 16115358
Drug: Control dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control dairy products (0.17 g c9,t11 CLA/d; 0.31 g tVA/d)
Study: 10051075
Drug: Prone position
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prone position with inhaled nitric oxide (10 ppm)
Study: 10051075
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of nitric oxide (10 ppm) in supine position
Study: 10051075
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prone position and inhaled nitric oxide
Study: 31807849
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (DES) with paclitaxel
Study: 21251129
Drug: Moxifloxacin (positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (positive control drug)
Study: 12898456
Drug: Alanine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alanine (1.5 mg. kg(‐1). min(‐1))
Study: 3904885
Drug: Sulpiride (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (2000 mg/day, range 800-3200)
Study: 3904885
Drug: Haloperidol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (12 mg/day, range 6-24)
Study: 30797750
Drug: Levothyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine treatment for patients with thyroid-stimulating hormone values of more than 10 mIU/L
Study: 30797750
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of therapy for abnormal thyroid function
Study: 31659776
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (PC)
Study: 26882833
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg of 5% ketamine)
Study: 26882833
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg of 2% lidocaine)
Study: 23093664
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (0.3 units · kg(‐1))
Study: 23093664
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (0.6 units · kg(‐1))
Study: 23093664
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (1.2 units · kg(‐1))
Study: 19969374
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus atomoxetine (40‐120 mg/d)
Study: 9660375
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of oral d‐fenfluramine (d‐FEN)
Study: 7640447
Drug: Peritoneal lavage
Normalized name: Peritoneal Lavage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal lavage with intravenous antibiotic therapy (aminoglycoside and cephem)
Study: 7640447
Drug: Silicon tube
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicon tube drainage with the same systemic antibiotic therapy
Study: 2751138
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg tetracaine with 0.2 mg epinephrine
Study: 2751138
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg tetracaine alone
Study: 2751138
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tetracaine
Study: 30538075
Drug: Telmisartan co-administration
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan co-administration
Study: 27080379
Drug: Subarachnoid morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid morphine (100μg)
Study: 25052334
Drug: 21 mg
Normalized name: aspirin 421 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg nicotine patches for four weeks before quitting, whilst smoking as normal
Study: 25052334
Drug: Not using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not using nicotine patches
Study: 19726362
Drug: PA‐MSHA treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA‐MSHA treatment in addition to neoadjuvant chemotherapy
Study: 19726362
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with neoadjuvant chemotherapy
Study: 9893549
Drug: Sufentanil 2
Normalized name: SUFentanil 250 MCG in 5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 2 micrograms.ml‐1
Study: 8179658
Drug: Nicotine 2
Normalized name: nicotine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 2 mg chewing gum
Study: 8179658
Drug: Nicotine 4
Normalized name: nicotine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 4 mg chewing gum
Study: 8179658
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (gum and patch)
Study: 2636484
Drug: Ultraviolet light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultraviolet light treatment of 50 ml venous blood
Study: 8436158
Drug: Allomaron (allopurinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allomaron (allopurinol 100 mg plus benzbromarone 20 mg)
Study: 8436158
Drug: Zyloprim (allopurinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zyloprim (allopurinol 100 mg)
Study: 749193
Drug: Concurrent hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent hormonal therapy with combination chemotherapy